@article{3fdf083552c94b1bbdf852f6ea80b5b8,
title = "Strategies and Foundations for Scientific Discovery in Longitudinal Studies of Bipolar Disorder",
abstract = "Bipolar disorder (BD) is a complex and dynamic condition with a typical onset in late adolescence or early adulthood followed by an episodic course with intervening periods of subthreshold symptoms or euthymia. It is complicated by the accumulation of comorbid medical and psychiatric disorders. The etiology of BD remains unknown and no reliable biological markers have yet been identified. This is likely due to lack of comprehensive ontological framework and, most importantly, the fact that most studies have been based on small nonrepresentative clinical samples with cross-sectional designs. We propose to establish large, global longitudinal cohorts of BD studied consistently in a multidimensional and multidisciplinary manner to determine etiology and help improve treatment. Herein we propose collection of a broad range of data that reflect the heterogenic phenotypic manifestations of BD that include dimensional and categorical measures of mood, neurocognitive, personality, behavior, sleep and circadian, life-story, and outcomes domains. In combination with genetic and biological information such an approach promotes the integrating and harmonizing of data within and across current ontology systems while supporting a paradigm shift that will facilitate discovery and become the basis for novel hypotheses.",
author = "McInnis, {Melvin G} and Andreassen, {Ole A} and Andreazza, {Ana C} and Uri Alon and Michael Berk and Teri Brister and Burdick, {Katherine E} and Donghong Cui and Mark Frye and Marion Leboyer and Mitchell, {Philip B} and Kathleen Merikangas and Nierenberg, {Andrew A} and Nurnberger, {John I} and Daniel Pham and Eduard Vieta and Yatham, {Lakshmi N} and Young, {Allan H}",
note = "Funding Information: We gratefully acknowledge the support of the Baszucki Brain Research Fund, the National Alliance on Mental Illness (NAMI), and the Milken Institute Center for Strategic Philanthropy. MGM is supported by the HC Prechter Bipolar Research Program, the Richard Tam Foundation, NIMH (MH114835 & UL1TR002240). AAN Supported, in part, by the Dauten Family Center for Bipolar Treatment Innovation and the Thomas P. Hackett, MD Chair in Psychiatry at Massachusetts General Hospital. MB is supported by a NHMRC Senior Principal Research Fellowship (1156072). KEB is supported by NIH R01MH124381. PBM is supported by an Australian NHMRC Investigator Grant (1177991). EV thanks the support of the Spanish Ministry of Science and Innovation (PI15/00283, PI18/00805) integrated into the Plan Nacional de I+D+I and co‐financed by the ISCIII‐Subdirecci{\'o}n General de Evaluaci{\'o}n and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria d{\textquoteright}Universitats i Recerca del Departament d{\textquoteright}Economia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357. AHY independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the UK Department of Health. OAA is supported by the Research Council of Norway (223273). Funding Information: MGM has received consulting fees and research support from Janssen Pharmaceuticals. AAN received consulting fees, grants, or honoraria from Alkermes, Belvior Publishing, Ginger Inc., Merck, Myriad, Neuronetics, Patient Centered Outcomes Research Institute, Physician's Postgraduate Press, Protagenics, Slack Publishing, Sunovion, UpToDate Wolters Kluwer, and Wiley Publishing. JIN has received research support from Janssen Pharmaceuticals. MAF has financial interest in Chymia LLC and has received grant support from Assurex Health and the Mayo Foundation. LNY has been a speaker or a member of advisory board or received research grants from Alkermes, Abbvie, Allergan, Canadian Network for Mood and Anxiety Treatments, Canadian Institutes of Health Research, Sumitomo Dainippon Pharma, GlaxoSmithKline, Intracellular Therapies, Merck, Sanofi, and Sunovion, over the last 3 years. OAA is a consultant to HealthLytix, received speaker´s honorarium from Lundbeck and Sunovion. MB has received Grant/Research Support from the Wellcome Trust, Australian Research Council, Victorian Medical Research Accelerator Fund, Stanley Medical Research Foundation, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a consultant or speaker for Allergan, Eisai, Janssen and Janssen, Lundbeck, Merck, and Servier – all unrelated to this work. AHY has provided paid lectures and been a member on advisory boards for the following companies with drugs used in affective and related disorders: Astrazenaca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, COMPASS, Sage, Novartis; all unrelated to this work. EV has received grants and served as consultant, advisor or CME speaker for the following entities (unrelated to the present work): AB‐Biotics, Abbvie, Aimentia, Angelini, Biogen, Celon, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, GH Research, Glaxo Smith‐Kline, Janssen, Lundbeck, Organon, Otsuka, Sage, Sanofi‐Aventis, Sunovion, and Takeda Funding Information: We gratefully acknowledge the support of the Baszucki Brain Research Fund, the National Alliance on Mental Illness (NAMI), and the Milken Institute Center for Strategic Philanthropy. MGM is supported by the HC Prechter Bipolar Research Program, the Richard Tam Foundation, NIMH (MH114835 & UL1TR002240). AAN Supported, in part, by the Dauten Family Center for Bipolar Treatment Innovation and the Thomas P. Hackett, MD Chair in Psychiatry at Massachusetts General Hospital. MB is supported by a NHMRC Senior Principal Research Fellowship (1156072). KEB is supported by NIH R01MH124381. PBM is supported by an Australian NHMRC Investigator Grant (1177991). EV thanks the support of the Spanish Ministry of Science and Innovation (PI15/00283, PI18/00805) integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII-Subdirecci{\'o}n General de Evaluaci{\'o}n and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria d{\textquoteright}Universitats i Recerca del Departament d{\textquoteright}Economia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357. AHY independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the UK Department of Health. OAA is supported by the Research Council of Norway (223273). Publisher Copyright: {\textcopyright} 2022 The Authors. Bipolar Disorders published by John Wiley & Sons Ltd.",
year = "2022",
month = aug,
doi = "10.1111/bdi.13198",
language = "English",
volume = "24",
pages = "499--508",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Blackwell Munksgaard",
number = "5",
}